TOP 100 MEDICAL SITES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lee National Denim Day-Share Your Heart - Video Felicity Huffman Named 2010 Lee National Denim Day Ambassador, Wears Her Jeans and Helps Celebrate 15 Years Fighting Breast Cancer feedproxy.google.com |
Clarient, Generation Health Sign Agreement to Provide, Manage Genetic Testing (PR Newswire) Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced a new contractual agreement with Generation Health, Inc. . Â This agreement makes Clarient a preferred genetic testing lab for GH, thereby ensuring reimbursement of diagnostic tests done for GH's nationwide network of payor clients and expanding Clarient's potential market. us.rd.yahoo.com |
Shire Plc. Q2 2010 Earnings Call Transcript Shire Plc. (SHPGY)Q2 2010 Earnings CallAugust 04, 2010 9:00 am ETComplete Story » seekingalpha.com |
Interview: Cleveland BioLabs CEO Discusses Recent Developments, Milestones Ahead M.E. Garza submits: We are hearing some very loud and credible chatter that long-awaited good news may be coming for Cleveland BioLabs (CBLI), the company that engages in the discovery, development, and commercialization of products for human protection from radiation.In the first quarter of this year, the company submitted additional paperwork about Protectan CBLB502 (a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy) to a potential customer - the U.S. Government's Department of Defense. Many on Wall Street believe that the company has the best chance of not only getting significant funding from the DoD, but also a potentially bigger order from the Biomedical Advanced Research and Development Authority (BARDA) who would acquire doses of the drug for the Strategic National Stockpile.Complete Story » seekingalpha.com |
Zimmer Holdings: Nothing to Get Excited About Margin of Safety Investing submits: Zimmer Holdings (ZMH) is a leader in knee and hip implants and plays in a number of other orthopedic niches. The company was added to the idea pipeline as Morningstar rates it a 5-star wide moat company. ZMH’s stock is currently trading at $51-52. 1- Business Performance Risk (=) and intrinsic returns (=)Complete Story » seekingalpha.com |